Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections

Buckley, Peter T.; Chan, Rita; Fernandez, Jeffrey; Luo, Jinquan; Lacey, Keenan A.; DuMont, Ashley L.; O’Malley, Aidan; Brezski, Randall J.; Zheng, Songmao; Malia, T.; Whitaker, Brian; Zwolak, Adam; Payne, Angela; Clark, Desmond; Sigg, Martin; Lacy, Eilyn R.; Kornilova, A. D.; Kwok, Debra; McCarthy, Steve; Wu, Bingyuan; Morrow, Brian J.; Nemeth-Seay, Jennifer; Petley, Ted; Wu, Sam; Strohl, William R.; Lynch, A. Simon; Torres, Victor J.

doi:10.1016/j.chom.2023.04.004

Cited by 13 publications

(11 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, recent advancements in mAbs have shifted toward a multivalent combinatorial model, including mAb cocktails with multiple epitope binding sites, which encompass the neutralizing antigen to a greater extent, closely resembling the human natural immune system [54,55]. A recent study proposes an engineered, multivalent protein biologic agent that targets five surface proteins and neutralizes five different S. aureus virulence factors [56]. It is designed to resist proteolysis, avoid Fc binding to S. aureus IgG-binding proteins, and neutralize toxins.…”

Section: Current Research and Clinical Trialsmentioning

confidence: 99%

Monoclonal Antibodies as a Therapeutic Strategy against Multidrug-Resistant Bacterial Infections in a Post-COVID-19 Era

Chen,

Pan,

Chen

et al. 2024

Life

View full text Add to dashboard Cite

The development of severe multidrug-resistant bacterial infections has recently intensified because of the COVID-19 pandemic. According to the guidelines issued by the World Health Organization (WHO), routine antibiotic administration is not recommended for patients with supposed or confirmed mild SARS-CoV-2 infection or pneumonia, unless bacterial infection is clinically suspected. However, recent studies have pointed out that the proportion of non-essential antibiotic use in patients infected with SARS-CoV-2 remains high. Therefore, the silent pandemic of antibiotic resistance remains a pressing issue regardless of the present threats presented by the COVID-19 pandemic. To prevent or delay entry into the postulated post-antibiotic era, the long-term advocacy for the rational use of antibiotics, the optimization of infection control procedures, and the development of new antibacterial agents and vaccines should be underscored as vital practices of the antibacterial toolbox. Recently, the development of vaccines and monoclonal antibodies has gradually received attention following the advancement of biotechnology as well as enhanced drug discovery and development in cancer research. Although decent progress has been made in laboratory-based research and promising results have been obtained following clinical trials of some of these products, challenges still exist in their widespread clinical applications. This article describes the current advantages of antibacterial monoclonal antibodies, the development of associated clinical trials, and some perceived future perspectives and challenges. Further, we anticipate the development of more therapeutic agents to combat drug-resistant bacterial infections as well as to increase the resilience of current or novel agents/strategies.

show abstract

Section: Current Research and Clinical Trialsmentioning

confidence: 99%

Monoclonal Antibodies as a Therapeutic Strategy against Multidrug-Resistant Bacterial Infections in a Post-COVID-19 Era

Chen,

Pan,

Chen

et al. 2024

Life

View full text Add to dashboard Cite

show abstract

“…Compared with parental monoclonal antibodies, SM1B74 enhanced phagocyte-mediated killing and protected phagocytes. In animal models, SM1B74 synergized with the antibiotic vancomycin, resulting in enhanced clearance of S. aureus (Buckley et al, 2023).…”

Section: Antibodiesmentioning

confidence: 99%

Advances in the targeted theragnostics of osteomyelitis caused by Staphylococcus aureus

Abdulrehman,

Qadri,

Haik

et al. 2024

Arch Microbiol

View full text Add to dashboard Cite

“…For patients in critical care units or undergoing planned surgery, a vaccine that triggers an immediate protective response against S. aureus infection would be ideal [15]. The 4C-Staph vaccine, when appropriately adjuvanted, may help to accomplish this [15]. In a study, a novel small molecule targeting TLR7 adsorbed to alum was added to 4C-Staph to create 4C-Staph/T7-alum [15].…”

Section: Application Of S Aureus Vaccinesmentioning

confidence: 99%

Updates on Staphylococcal Vaccines

Scafa-Udriste,

Popa,

Popa

2023

Microbiology Research

View full text Add to dashboard Cite

Staphylococcus aureus, a prevalent human pathogen and a leading cause of hospital-acquired infections, is increasingly evolving antibiotic-resistant strains, increasing mortality and morbidity rates. Anti-staphylococcal vaccine research for prevention and treatment has become a priority. Antibodies against specific S. aureus components, toxins, and polysaccharides have demonstrated encouraging results in animal studies regarding protection against colonization or infection. However, human immunization trials have yielded less optimistic outcomes, with no anti-staphylococcal having passed clinical trials up to now. Although multiple formulation attempts triggered strong antibody responses, the vaccines could not effectively prevent S. aureus infections. This article delves into the results of immunotherapeutic strategies against S. aureus in both animal and human studies, discussing the feasibility of adequate immunization approaches against S. aureus in humans.

show abstract

Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections

Cited by 13 publications

References 83 publications

Monoclonal Antibodies as a Therapeutic Strategy against Multidrug-Resistant Bacterial Infections in a Post-COVID-19 Era

Monoclonal Antibodies as a Therapeutic Strategy against Multidrug-Resistant Bacterial Infections in a Post-COVID-19 Era

Advances in the targeted theragnostics of osteomyelitis caused by Staphylococcus aureus

Updates on Staphylococcal Vaccines

Contact Info

Product

Resources

About